Keyword index


Keyword index

  • absolute lymphocyte count, 217, 605
  • acquired immunodeficiency syndrome, 455
  • activation, 416
  • acute
  • acuteleukaemia, 421, 814
  • acutelymphatic leukemia, 117
  • acutelymphoblastic disease, 412
  • acutelymphoblastic leukaemia, 552, 766
  • acutemegakaryoblastic leukaemia (M7), 729
  • acutemyeloid leukaemia, 1, 42, 477, 576, 590, 601, 709
  • acutepromyelocytic leukaemia, 463
  • adenosine deaminase, 243
  • adhesion molecules, 804
  • admission requirements, 225
  • adult T-cell leukaemia, 568
  • adults, 90
  • advanced stage, 584
  • aggregation, 79
  • AL amyloidosis, 681
  • allele, 528
  • allogeneic, 435, 749
  • allogeneicbone marrow transplantation, 766
  • allogeneicstem cell transplantation, 217
  • alloimmune, 366
  • alternative donors, 58
  • altitude sickness, 369
  • AML1-ETO, 353
  • anaemia, 98, 99, 100, 101
  • anaesthesia, 79
  • antibodies, 167
  • anticoagulation, 12
  • antiretroviral therapy, 455
  • anti-sickling agent, 788
  • anti-thymocyte globulin, 408, 409
  • aplastic anaemia, 408, 409, 818
  • apoptosis, 156, 373, 416, 512, 560, 655
  • arsenic trioxide, 470, 512
  • asparaginase, 117
  • asparagine, 117
  • autoimmune cytopenia, 749
  • autoimmunity, 232, 400
  • autologous, 343, 749
  • autotransplantation, 24
  • bacterial-translocation, 282
  • B-cell
  • B-cellacute lymphoblastic leukaemia, 414
  • B-cellchronic lymphocytic leukaemia, 141
  • B-celldifferentiation, 373
  • B-cellnon-Hodgkin's lymphoma, 414
  • B cells, 180
  • Bcl-2, 655
  • bcr/abl, 213
  • B-domain-deleted factor VIII, 629
  • Bernard–Soulier syndrome, 95
  • beta-thalassaemia, 93
  • Bfl-1/A1, 373
  • biphenotypic, 814
  • biphenotypicleukaemia, 94
  • bisphosphonates, 93
  • bleeding disorders, 621
  • blood
  • bloodgroup, 528
  • bloodtransfusion, 83, 107
  • bone
  • bonedisease, 38
  • bonemarrow biopsy, 538
  • bonemarrow transplantation, 435
  • B-prolymphocytic leukaemia, 330
  • β-thromboglobulin, 74
  • C2 domain, 629
  • cancer, 100
  • carcinoembryonic antigen-related cell adhesion molecule 8, 666
  • caspase, 655
  • cataracts, 796
  • CD47, 412
  • CD20, 701
  • CD21, 180
  • CD90/Thy1, 203
  • cDNA microarray, 576
  • CD34+
  • CD34+ cell dose, 605
  • CD34+ selection, 58
  • cell cycle, 141
  • central nervous system relapse, 766
  • chemokines, 38
  • chemoresistant, 756
  • chemotherapy, 681
  • childhood, 117, 412
  • childhood acute lymphoblastic anaemia, 410
  • children, 414
  • chromosome 12q24, 815
  • chronic
  • chronicgraft versus host disease, 435
  • chronichepatitis C, 769
  • chroniclymphocytic leukaemia, 294, 720
  • chroniclymphocytic leukaemia cells, 128
  • chronicmyeloid leukaemia, 187, 213, 500, 613
  • ciclosporin, 408
  • cisplatin, 756
  • classical Hodgkin's disease, 701
  • clinical
  • clinicaloutcome, 358
  • clinicalpharmaeology, 117
  • clinicaltrial, 470
  • coagulant activity, 638
  • coagulation, 369
  • coagulationfactors, 69
  • coagulationtests, 69
  • complications, 538
  • compound heterozygosity, 817
  • computed tomography guidance, 538
  • computerized drug prescription, 50
  • congenital
  • congenitalbleeding disorder, 769
  • congenitalfactor VII deficiency, 494
  • congenitalhaemolytic anaemia, 796
  • congenitalplatelet function disorders, 95
  • congenitalpolycythaemia, 537
  • cord blood, 3
  • cord bloodbanking, 358
  • cord bloodstem cells, 358
  • cycline E, 141
  • cyclophosphamide, 408
  • cytarabine, 756
  • cytogenetics, 552
  • cytomegalovirus, 107
  • cytotoxicity, 343
  • darbepoetin alfa, 101
  • deferiprone, 545
  • deletion of 20q, 337
  • dendritic
  • dendriticcell activation, 392
  • dendriticcells, 343, 720, 743
  • depsipeptide, 156
  • desferrioxamine, 545
  • diagnosis, 435, 681
  • Diamond Blackfan anaemia, 243
  • diffuse large B-cell lymphoma, 605
  • disease stage, 128
  • dominant negative, 31
  • double strand break, 318
  • Down's syndrome, 729
  • drug management, 50
  • E4BP4, 560
  • E2A-HLF, 560
  • early response, 149
  • endothelial cell
  • endothelial cell activation, 415
  • endothelial cell apoptosis, 415
  • endothelial cells, 804
  • endothelial microparticles, 416
  • epidemiology, 90
  • epoetin, 100
  • epoetin beta, 98, 101
  • Epstein–Barr virus, 267
  • erythrocyte, 528
  • erythrocytosis, 537
  • erythropoietin, 98, 99, 537
  • erythropoietin receptor mutation, 537
  • etoposide, 756
  • Evans's syndrome, 749
  • event free survival, 552
  • exercise, 369
  • exon skipping, 253
  • expression profiling, 576
  • extended intrathecal therapy, 766
  • extracellular
  • extracellular matrix, 416
  • extracellular phosphorylation, 74
  • factor VII, 494
  • Factor VIII, 629
  • factor XI deficiency, 817
  • familial
  • familial chronic lymphocytic leukaemia, 815
  • familial polycythaemia, 537
  • Fc receptors, 167
  • fibrinolysis, 12
  • flow cytometry, 777, 804
  • FLT-3 aberrations, 463
  • fluorescence in situ hybridization, 64, 337
  • freeze-drying, 240
  • fresh frozen plasma, 69
  • fungal infection, 217
  • gammaglobulins, 232
  • gene expression profile, 373
  • genetic
  • genetic counselling, 243
  • genetic imprinting, 621
  • genetic variation, 421
  • genetics of thrombosis and haemostasis, 621
  • Glanzmann's thrombasthenia, 95
  • glycosyltransferase, 528
  • GPI-anchored protein, 383
  • graft versus host disease, 480
  • granules, 666
  • granulocyte colony-stimulating factor, 666
  • growth factors, 282
  • guidelines, 294
  • gut decontamination, 282
  • haematological, 282
  • haematologicalmalignancies, 196
  • haematologicalmalignancy, 101
  • haematologicalresponse, 818
  • haematologicalstem cell recipients, 196
  • haematopoiesis, 655
  • haematopoietic stem
  • haematopoietic stem cellcell transplant, 405
  • haematopoietic stem cellcell transplantation, 3, 613
  • haematopoietic stemcells, 358
  • haemolytic anaemia, 253
  • haemophilia, 366, 769
  • haemophilia A, 629
  • haemosiderosis, 545
  • haemostasis, 69, 638
  • heart, 545
  • Heerlen allele, 647
  • hepatomegaly, 796
  • hepatotoxicity, 410
  • hereditary
  • hereditaryhemochomatosis classification, 674
  • hereditaryhemochromatosis type III, 674
  • hereditarystomatocytosis, 521
  • high
  • highgraft rejection, 406
  • hightransplant-related mortality, 406
  • high-dose cyclophosphamide, 409
  • histone deacytylase inhibitors, 156
  • Hodgkin's
  • Hodgkin'sdisease, 455
  • Hodgkin'slymphoma, 267, 584
  • Human hepatocyte, 638
  • human
  • humanimmunodeficiency virus, 455
  • humanleucocyte antigen-identical donor, 225
  • humanT-cell leukaemia virus type I, 568
  • hybrid chemotherapy regimen, 584
  • hydrogen peroxide, 512
  • hypodiploidy, 552
  • hypoxanthine-guanine phosphoribosyltransferase gene, 383
  • hypoxia, 369
  • idiopathic thrombocytopenic purpura, 90, 90
  • Ikaros, 31
  • imatinib, 187, 500
  • immune
  • immunedeficiencies, 720
  • immunerecovery, 455
  • immunethrombocytopenia, 400, 749
  • immunethrombocytopenic purpura, 232
  • immunoglobulin heavy chain translocation, 64
  • immunophenotype, 180, 701
  • immunosuppression, 400
  • immunotherapy, 267, 343, 743
  • in vitro screening, 353
  • incidence, 90, 90
  • inhibitors, 366
  • innate immunity, 392
  • insulin-like growth factor-1, 91
  • interferon-α, 568
  • interleukin-12, 743
  • invasive aspergillosis, 196, 392
  • iron
  • iron chelation, 545
  • iron overload onset, 674
  • ischaemic stroke, 777
  • isochromosome, 337
  • isoform, 31
  • Japanese, 480
  • leucocyte–platelet complexes, 777
  • leukaemia, 31, 560, 709
  • leukaemia classification, 94
  • leukaemia therapy, 421
  • leukaemogenesis, 353
  • LightCyclerTM PCR, 196
  • long-term culture, 638
  • lymphocyte recovery, 217
  • lymphoproliferative malignancy, 98, 99
  • major histocompatibility complex, 167
  • malignancy, 282
  • management, 294
  • mantle cell lymphoma, 330
  • marrow transplantation, 480
  • matrix
  • matrix metalloproteinase  9, 128
  • matrix remodelling, 128
  • Mcl-1, 655
  • MDR1 expression, 477
  • methylprednisolone, 756
  • microarray, 729
  • minimal residual disease, 590
  • molecular analysis, 621
  • monoclonal protein, 162
  • mucosa-associated lymphoid tissue lymphoma, 318
  • multiple myeloma, 24, 38, 96, 149, 156, 162, 470, 743
  • mutant frequency, 383
  • mutation, 817
  • myelodysplastic
  • myelodysplastic syndrome, 709
  • myelodysplastic syndromes, 576
  • myeloid disease, 337
  • myeloma, 64, 373, 756
  • MYST4-CBP fusion transcript, 601
  • Na+–K+-leaky red cell disorders, 521
  • natural killer cells, 167, 400
  • neutropenia, 232
  • neutrophils, 666
  • non-Hodgkin's lymphoma, 180
  • non-homologous end joining, 318
  • non-myeloablative
  • non-myeloablativeallotransplantation, 24
  • non-myeloablativeconditioning, 225
  • non-myeloablativetransplant, 406
  • novel drugs, 24
  • obesity, 538
  • Omenn syndrome, 406
  • once-weekly administration, 98
  • osteoporosis, 91, 93
  • osteoprotegerin, 91, 93
  • p27, 141
  • paediatric, 405
  • PAI-1, 12
  • paroxysmal nocturnal haemoglobinuria, 383, 408, 804
  • pegylated rHuMGDF, 818
  • peripheral blood progenitor cells, 605
  • permeability, 282
  • pharmacokinetics, 96, 149, 494
  • phosphatidylinositol-3 kinase, 500
  • phosphoinositide-3 kinase, 512
  • PKLR pre-mRNA processing, 253
  • plasma cells, 373
  • plasmacytoid dendritic cells, 568
  • plasminogen activator, 12
  • platelet, 79, 107
  • plateletactivation, 74, 777
  • plateletconcentrates, 83
  • plateletfunction, 621
  • platelettransfusion, 95
  • pluripotent, 353
  • polymerase chain reaction, 196
  • polymorphism, 243
  • poor-risk cytogenetics, 203
  • population based, 90
  • prescription errors, 50
  • prognosis, 337, 701, 814
  • prognostic
  • prognosticfactor, 42, 64
  • prognosticfactors, 162, 180
  • prognosticmodel, 477
  • prophylaxis, 494
  • propofol, 79
  • protein S deficiency, 647
  • pseudohyperkalaemia, 521
  • pulmonary
  • pulmonaryhypertension, 405
  • pulmonarysequestration, 788
  • pure red cell aplasia, 749
  • purinergic receptor, 815
  • P2X7, 815
  • pyruvate kinase deficiency, 253
  • 5q- syndrome, 576
  • quality of life, 149
  • real-time quantitative RT-PCR, 590
  • recombinant factor VIIa, 95, 494
  • red blood cells, 253, 412
  • reduced-intensity preparative regimens, 3
  • Reed–Sternberg cells, 701
  • refractoriness, 83
  • refractory disease, 470
  • relapse, 477
  • relapsed disease, 470
  • renal failure, 96
  • response, 162
  • Rh
  • Rhantigens, 412
  • RhD- -, 412
  • Rhnull, 412
  • risk
  • riskassessment, 613
  • riskscore, 613
  • rituximab, 232, 366, 414
  • Roscovitine, 141
  • RPS19 mutations, 243
  • runt-related transcription factor 1, 709
  • R105X novel mutation, 674
  • secondary AML, 203
  • secretion, 629, 638
  • seizures, 796
  • severe
  • severeaplastic anaemia, 58
  • severecombined immunodeficiency, 406
  • severecombined immunodeficiency syndrome, 405
  • sickle cell disease, 3, 788, 804
  • signal transduction, 512
  • single nucleotide polymorphism, 815
  • splice site defect, 647
  • stability studies, 240
  • statistical hypothesis, 99
  • stem cell
  • stem cellharvest, 756
  • stem cellline, 353
  • stem celltransplant, 64
  • stem celltransplantation, 225, 480, 681, 749
  • stomatin, 796
  • subcellular fractionation, 666
  • survival, 24, 162
  • systemic lupus erythematosus, 74
  • t(11:18)(q21;q21), 318
  • t(11;14), 330
  • t(8;21), 477
  • t(10;16), 601
  • t(4;11), 31
  • T cell response, 213
  • T cells, 720
  • temperature dependence, 521
  • TFR2α receptor function, 674
  • thalassaemia, 3, 91
  • thalidomide, 96, 149
  • therapy, 366, 814
  • 6-thioguanine, 410, 412
  • thiopental, 79
  • thiopurines, 410, 412
  • thrombin, 12
  • thromboplastin reference preparations, 240
  • thrombosis, 74
  • thrombotic thrombocytopenic purpura, 225, 415, 416
  • tissue infiltration, 128
  • toll-like receptors, 392
  • transcription factor, 709
  • transferrin receptor
  • transferrin receptor1, 42
  • transferrin receptor 2, 42
  • transforming growth factor β, 743
  • transfusion, 528
  • transgenic sickle mice, 788
  • transient
  • transientischaemic attack, 777
  • transientmyeloproliferative disorder, 729
  • transjugular liver biopsy, 769
  • transmission, 107
  • transplantation, 358
  • treatment, 435, 681
  • tumour
  • tumourcell contamination, 605
  • tumourimmunity, 167
  • U266, 156
  • unrelated donors, 3
  • vaccines, 343, 720
  • validation, 613
  • vanillin prodrug, 788
  • variant Philadelphia chromosome, 187
  • veno-occlusive disease, 410, 412
  • WT1 gene transcript, 590
  • zoledronic acid, 91

Ancillary